A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women

Scandinavian Journal of Infectious Diseases
G Gossius, L Vorland

Abstract

The efficacy of a single-dose (4 tablets) trimethoprim-sulfamethoxazole (TMP-SMX) was compared with that of a 3-day and 10-day treatment with TMP-SMX, 2 tablets twice daily, in 464 female out-patients with symptoms denoting acute, uncomplicated urinary tract infection (UTI). 321 patients (70%) had significant bacteriuria. Treatment effect could be assessed in 279 women. Comparable results were obtained with the 3 regimens 2 and 6 weeks after treatment. Eradication of the initial organism occurred in 96% with single-dose, in 96-94% with a 3-day, and in 98% with a 10-day course. The incidence of adverse reactions was significantly greater in patients treated with a 10-day (28%) than in those treated with a single-dose (5%), or 3-day (9%) regimen (p less than 0.01). This study suggests that short treatment regimens for uncomplicated UTI in women are as effective as and cause fewer side-effects than the conventional 10-day chemotherapy.

References

Jul 1, 1979·The Journal of Antimicrobial Chemotherapy·J D AndersonR K Percival-Smith
May 5, 1979·British Medical Journal·G Källenius, J Winberg
Jan 17, 1976·British Medical Journal·C A CharltonS Rye
Sep 9, 1967·British Medical Journal·R N Grüneberg, W Brumfitt
Nov 14, 1981·British Medical Journal·J RapoportF W O'Grady
Jan 1, 1982·Reviews of Infectious Diseases·P Souney, B F Polk
Mar 1, 1982·Reviews of Infectious Diseases·N E Tolkoff-RubinR H Rubin
Mar 1, 1982·Reviews of Infectious Diseases·G W CountsM Turck
Nov 1, 1981·The American Journal of Medicine·C M Kunin

❮ Previous
Next ❯

Citations

Jan 1, 1987·Antimicrobial Agents and Chemotherapy·R A Gleckman
Jun 1, 1989·Antimicrobial Agents and Chemotherapy·C I Backhouse, J A Matthews
Aug 1, 1989·Antimicrobial Agents and Chemotherapy·T M HootonW E Stamm
Apr 28, 2004·Journal of General Internal Medicine·Michael B Rothberg, John B Wong
Jun 24, 2010·Expert Opinion on Emerging Drugs·Florian M E WagenlehnerKurt G Naber
Nov 8, 2005·The American Journal of Medicine·Eugene A KatchmanLeonard Leibovici
Jan 1, 1990·Scandinavian Journal of Infectious Diseases·G ReidM Llano
Jul 23, 2008·The Cochrane Database of Systematic Reviews·Monika Lutters, Nicole B Vogt-Ferrier
Apr 23, 2005·The Cochrane Database of Systematic Reviews·G MiloL Leibovici
Nov 1, 1992·The Journal of International Medical Research·J Guibert, M H Capron
May 1, 1987·Scandinavian Journal of Primary Health Care·J Sander

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.